Pfizer (PFE)
24.24
-0.02 (-0.08%)
NYSE · Last Trade: Jun 27th, 3:07 AM EDT
The panel also voted to recommend Merck’s RSV antibody drug Enflonsia for newborns whose mothers didn’t receive prenatal protection.
Via Stocktwits · June 26, 2025
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability.
Via Benzinga · June 26, 2025
Afshar was promoted last year to oversee sales and manufacturing operations in North America and Europe. He previously worked in the office of the CEO.
Via Stocktwits · June 26, 2025
During the study, 48 people living with hemophilia were treated with Hympavzi and observed to have a 93% reduction in annualized bleeding rate in 12 months.
Via Stocktwits · June 26, 2025
Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts.
Via Benzinga · June 26, 2025
RFK Jr.'s newly appointed CDC panel, half of whom oppose vaccines, prepares to review key data on COVID, RSV, and flu shots.
Via Stocktwits · June 25, 2025
Over the past six months, Pfizer’s shares (currently trading at $24.29) have posted a disappointing 8.5% loss while the S&P 500 was flat. This may have investors wondering how to approach the situation.
Via StockStory · June 25, 2025
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Via StockStory · June 23, 2025
Pfizer’s first quarter results drew a positive market response as management emphasized margin improvement and disciplined expense control, even as revenue declined. CEO Albert Bourla credited robust execution in key therapeutic areas, particularly oncology and internal medicine, for helping offset lower sales from COVID-related products. CFO Dave Denton highlighted the impact of productivity programs and a refined commercial approach, noting that adjusted operating expenses fell meaningfully due to ongoing cost realignment. Management acknowledged external pressures, including U.S. policy changes and lower COVID demand, but pointed to operational efficiency as a key factor supporting profitability.
Via StockStory · June 23, 2025
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
Via Benzinga · June 20, 2025
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Via StockStory · June 20, 2025
Looking for the most active stocks in the S&P500 index on Wednesday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · June 18, 2025
Via Benzinga · June 18, 2025
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · June 17, 2025
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such as Ireland and Bermuda, according to CNBC.
Via Stocktwits · June 17, 2025
Via The Motley Fool · June 17, 2025
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Via StockStory · June 17, 2025
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Via StockStory · June 16, 2025
Jefferies thinks big pharma companies are "still on the hunt" for deals.
Via Stocktwits · June 13, 2025
Looking for the most active stocks in the S&P500 index on Friday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · June 13, 2025
The U.S. Food and Drug Administration expanded approval of Moderna Inc.'s (NASDAQ: MRNA) respiratory syncytial virus vaccine.
Via Benzinga · June 13, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 8.4%. This drawdown was discouraging since the S&P 500 held its ground.
Via StockStory · June 13, 2025